TY - JOUR
T1 - Modified FOLFOX6 (mFOLFOX6) in metastatic colorectal carcinoma patients with poor performance status
AU - Nishi, Tomohiro
AU - Hamamoto, Yasuo
AU - Uemoto, Junko
AU - Onodera, Kei
AU - Warita, Etsuko
AU - Yamanaka, Yasuhiro
N1 - Copyright:
Copyright 2016 Elsevier B.V., All rights reserved.
PY - 2012/12
Y1 - 2012/12
N2 - Because mFOLFOX6 has few contraindications, it is useful for poor performance status (PS) cases. However, in Japan, there are some reports that the dose is reduced easily. We retrospectively examined the safety/usefulness of the full dose mFOLFOX6 (first-line) for advanced colon cancer patients with poor PS. Four of five cases had improved PS. The response rate was 60%. Grade 3/4 adverse events were infection, leukopenia, and neutropenia. Treatment-related deaths within 60 days of starting treatment were absent. Full-dose mFOLFOX6 for poor PS may be beneficial. However, we must consider the increased risk of adverse events.
AB - Because mFOLFOX6 has few contraindications, it is useful for poor performance status (PS) cases. However, in Japan, there are some reports that the dose is reduced easily. We retrospectively examined the safety/usefulness of the full dose mFOLFOX6 (first-line) for advanced colon cancer patients with poor PS. Four of five cases had improved PS. The response rate was 60%. Grade 3/4 adverse events were infection, leukopenia, and neutropenia. Treatment-related deaths within 60 days of starting treatment were absent. Full-dose mFOLFOX6 for poor PS may be beneficial. However, we must consider the increased risk of adverse events.
KW - MFOLFOX6
KW - Palliative chemotherapy
KW - Poor performance status
UR - http://www.scopus.com/inward/record.url?scp=84875029958&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84875029958&partnerID=8YFLogxK
M3 - Article
C2 - 23235179
AN - SCOPUS:84875029958
SN - 0385-0684
VL - 39
SP - 2557
EP - 2560
JO - Japanese Journal of Cancer and Chemotherapy
JF - Japanese Journal of Cancer and Chemotherapy
IS - 13
ER -
